AstraZeneca

News

AZ sees triple approval in Japan for cancer and COPD drugs

AstraZeneca has seen three of its drugs approved by the Japanese regulator – a new indication for its cancer drug Lynparza, and two new combination therapies for patients with chronic obstr

News

AZ prepares for showdown with AbbVie/J&J as Calquence shines...

AstraZeneca has announced data showing its cancer drug Calquence outperformed standard care in chronic lymphocytic leukaemia – reducing risk of disease progression or death by 69%.

News

Cost of AZ’s new Cambridge HQ ‘has more than doubled’

The cost of AstraZeneca’s new R&D hub and corporate headquarters in Cambridge has swelled to £750 million, more than twice the original estimate, says a report in The Times.

News

AstraZeneca ends another Calquence trial early

For the second time in the space of a month AstraZeneca has stopped a trial of its chronic lymphocytic leukaemia (CLL) drug Calquence (acalabrutinib) early following positive results.

News

AZ/Merck & Co wow ASCO with pancreatic cancer data

Finding targeted therapies for pancreatic cancer has long been an issue for pharma, meaning that for decades the only real option has been a course of chemotherapy, with unpleasant side-eff

News

AZ/Merck & Co reveal data supporting PARP drug in prostate c...

PARP, or poly (ADP-ribose) polymerase, inhibitors may have an amusing-sounding name but an increasing body of evidence suggest they could be used in a wide range of cancers as long as certa

AZ sees triple approval in Japan for cancer and COPD drugs

AZ prepares for showdown with AbbVie/J&J as Calquence shines...

Cost of AZ’s new Cambridge HQ ‘has more than doubled’

AstraZeneca ends another Calquence trial early

AZ/Merck & Co wow ASCO with pancreatic cancer data

AZ/Merck & Co reveal data supporting PARP drug in prostate c...

An AI supercomputer and discovering next-gen brain disorder ...

How to meet your physicians where they are online

AstraZeneca

Editor's Picks